Efectos secundarios del tratamiento para la leucemia linfoblástica aguda .. ( PEG-L asparaginasa; Oncaspar®) administrada por inyección. O Vincristina. L-asparaginase, definition: alkylating anticancer drug used in the treatment of L -asparaginasa, definition: fármaco alquilante antineoplásico, utilizado para el Los efectos secundarios más comunes son nauseas, vómitos. y otros efectos adversos de este grupo de fármacos, ya que estos pacientes los efectos citotóxicos de la quimioterapia son mediados por diversos . Actinomicina D, metotrexato, andrógenos, L-asparaginasa, procarbazina, vincristina.
|Published (Last):||3 March 2011|
|PDF File Size:||10.33 Mb|
|ePub File Size:||16.23 Mb|
|Price:||Free* [*Free Regsitration Required]|
For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur.
Active treatment for graft-versus-host disease 6. The trial involves single site in the Member State l-asparaginaea.
Cancer AND drug name. Los sujetos deben haber finalizado todo tipo de inmunoterapia activa p. Son aptos los sujetos que hayan sufrido una alergia previa a la asparaginasa PEG pero l-asparwginasa puedan recibir Erwinia.
Subjects must have a serum creatinine level that is? Age 18 years or younger at the time of study treatment initiation. Subjects who have had a previous allergy to PEG-asparaginase but can receive Erwinia are eligible.
Time to toxicity will be evaluated to differentiate single-agent carfilzomib from carfilzomib in combination with induction chemotherapy? Combination product that includes a device, but does not involve an Advanced Therapy. Pneumonia AND sponsor name. How to search [pdf]. Known allergy to any of the drugs used in the study. Subjects must have fully recovered from the acute toxic effects of all k-asparaginasa chemotherapy, immunotherapy, or radiotherapy treatment before enrollment.
Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: Adequate liver function, defined as both of the following: Trials with results Trials without results.
Phase 1b – To assess the safety and tolerability of carfilzomib, alone and in combination with induction chemotherapy, for the treatment of children with relapsed or refractory acute lymphoblastic leukemia ALL -To determine the maximum tolerated dose MTD of carfilzomib in combination with induction chemotherapy.
Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial. Positive culture for bacteria or fungus l-asparaginaaa 14 days of the initiation of therapy 7. Subjects are under 18 years old.
The duration of this interval must be approved by the Onyx study medical monitor.
l-asparaginasa efectos adversos pdf – PDF Files
Both Female Only Male Only. The IMP has been designated in this adbersos as an orphan drug in the Community. Clear advanced search filters. EU Clinical Trials Register.
Trials with efsctos Trials without results Clear advanced search filters. Restricciones de tratamientos previos: IMP with orphan designation in the indication. Relapsed or Refractory Acute Lymphoblastic Leukemia.
Medicinas para Quimioterapia – Nombres de Medicina
Plans for treatment or care after the subject has ended the participation in the trial if it is different from the expected normal treatment of that condition. A group of cancers that usually begins in the bone marrow and results in high numbers of abnormal white blood cells. Review by the Competent Authority or Ethics Committee in the country concerned.
Karnofsky or Lansky scores? For these items you should use the filters and not add them to your search terms in the text field. Date ecectos which this record was first entered in the EudraCT database:. Title of the trial for lay people, in easily understood, i. Known allergy to Captisol a cyclodextrin derivative used to solubilize carfilzomib; for a complete listing of Captisol-enabled drugs, see the Ligand Pharmaceuticals, Inc.
Committee on Advanced therapies CAT has issued a classification for this product.